Abstract: Pen-type hazardous material applicators are provided having features useful in applying metal pretreatment material to intricate geometries, such as blind holes, through holes, rivets, crevices, chamfers, counterbores, countersinks and other difficult to access surfaces.

Abstract: Pen-type hazardous material applicators are provided useful in applying metal pretreatment material to intricate geometries, such as blind holes, through holes, rivets, crevices, chamfers, counterbores, countersinks and other difficult to access surfaces are provided.

Abstract: Embodiments of the present disclosure include methods and compositions related to CD105-targeting polypeptides. In some aspects, disclosed are chimeric receptors engineered to bind to CD105. Cells (e.g., NK cells, T-cells) expressing CD105-targeting peptides are described. Also described are therapeutic methods using polypeptides of the disclosure.

Abstract: Pen-type hazardous material applicators are provided useful in applying metal pretreatment material to intricate geometries, such as blind holes, through holes, rivets, crevices, chamfers, counterbores, countersinks and other difficult to access surfaces are provided.

Abstract: Disclosed herein, in some aspects, are immune cells comprising one or more engineered antigen receptors and one or more non-canonical CD6 isoforms and/or canonical CD6. Also disclosed are methods for cancer treatment comprising administering such immune cells to a subject in need thereof. Further disclosed are nucleic acids encoding a chimeric antigen receptor and a non-canonical CD6 isoform, and cells harboring same.

Abstract: A method and system provide for automated counting of prescription product and enables virtual verification of the dispensed prescription product. The method and system include capturing by a camera at a first site an image of the prescription product to be dispensed according to a prescription to a patient, electronically displaying the image on a display at a second site remote from the first site, and electronically transmitting a verification from the second site to the first site in response to the image of the prescription product being determined at the second site to be consistent with the prescription.

Abstract: A method and system provide for automated counting of prescription product and enables virtual verification of the dispensed prescription product. The method and system include counting a quantity of pills of a prescription product on a first portion of a tray, retaining the quantity of pills after the counting in a second portion of the tray, receiving at least the second portion of the tray into an imaging device, and capturing, with a first camera, an image of the quantity of pills in the second portion of the tray.

Abstract: A method and system provide for automated counting of prescription product and enables virtual verification of the dispensed prescription product. The method and system include counting a quantity of pills of a prescription product on a first portion of a tray, retaining the quantity of pills after the counting in a second portion of the tray, receiving at least the second portion of the tray into an imaging device, and capturing, with a first camera, an image of the quantity of pills in the second portion of the tray.

Abstract: A method and system provide for automated counting of prescription product and enables virtual verification of the dispensed prescription product. The method and system include counting a quantity of pills of a prescription product on a first portion of a tray, retaining the quantity of pills after the counting in a second portion of the tray, receiving at least the second portion of the tray into an imaging device, and capturing, with a first camera, an image of the quantity of pills in the second portion of the tray.

Abstract: Disclosed is a no-rinse aerospace cleaning composition useful in cleaning painted and unpainted metal, as well as polymeric surfaces found in aircraft, the composition comprising an oil-in-water emulsion containing water, organic solvent, an aqueous emulsion of wax-free glossing agent, solid particles, polyalkylsiloxane oil, surfactant, emulsifier, thickener, corrosion inhibitor, and pH adjuster; methods of making and using the composition are also provided.

Abstract: A valve assembly for a tire inflation/deflation system includes a body having a control port and a tire port, and a valve member for fluidly connecting or disconnecting the control port with the tire port. In one embodiment, the valve includes a fluid-operated damper having a damper chamber for controlling a timing of the valve member. A vent valve is provided for permitting excess fluid pressure to escape from the damper chamber. In another embodiment, the valve member includes a diaphragm separating first and second fluid chambers. A vent passage and at least one resilient fluid pressure-operated valve element are provided for enabling fluid to vent from the first chamber to the second chamber. Multiple-redundant valve elements may be provided to form an isolation gap that restricts contamination of the valve assembly.

Abstract: The subject invention concerns peptide mimetics of SOCS proteins and methods of use. In one embodiment, a peptide mimetic of the invention binds to a SOCS1 and a SOCS3 target protein. In a specific embodiment, a peptide mimetic of the invention comprises the amino acid sequence of SEQ ID NO:1 and/or SEQ ID NO:2 and/or SEQ ID NO:51, or a functional fragment or variant thereof. In a further embodiment, a peptide of the invention can comprise multiple copies of the mimetic sequence. In one embodiment, a peptide of the invention comprises two or more copies of SEQ ID NO:1 and/or SEQ ID NO:2 and/or SEQ ID NO:51. In a specific embodiment, a peptide mimetic of the invention comprises the amino acid sequence of SEQ ID NO:3 and/or SEQ ID NO:4 to and/or SEQ ID NO:52, or a functional fragment or variant thereof. The subject invention also pertains to methods of treating and/or preventing autoimmune conditions and/or disorders.

Abstract: Provided herein are methods of expanding CD161+ T cells. Also provided are methods and compositions for generating modified CD161+ T cells comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T cells are produced, expanded, and/or used in disease (e.g, cancer) treatments.

Abstract: Embodiments of the disclosure concern methods and compositions for delivering therapeutic, diagnostic or interventional moieties, such as complex and simple entities such as biologics, including at least cells, for example. The methods employ targeted delivery by employing at least one ALCAM-binding moiety on the therapeutic, diagnostic or interventional moiety to be delivered. In specific cases, the ALCAM-binding moiety is present on or with the therapeutic moiety in multiple iterations. In certain embodiments, the ALCAM-binding moiety comprises at least one SRCR domain from CD6 and a stalk, such as from CD6, of the secretable or molecular form thereof.

Abstract: Autodeposition coating compositions that deposit uncured coatings, on metallic surfaces of a substrate, which are curable at oven temperatures of less than 130° C., are provided as well as autodeposition methods, compositions and components for depositing such autodeposition coatings. More particularly, the invention relates to autodeposition coatings that cure at temperatures lower than conventional autodeposition coatings, while achieving chemical and corrosion performance comparable to higher temperature cure autodeposition coatings, as well as being directed to autodeposition coating compositions possessing improved storage stability and coating thermal stability, and articles of manufacture having cured and uncured autodeposited coatings deposited thereon.

Abstract: Embodiments of the disclosure concern methods and compositions for delivering therapeutic, diagnostic or interventional moieties, such as complex and simple entities such as biologies, including at least cells, for example. The methods employ targeted delivery by employing at least one ALCAM-binding moiety on the therapeutic, diagnostic or interventional moiety to be delivered. In specific cases, the ALCAM-binding moiety is present on or with the therapeutic moiety in multiple iterations. In certain embodiments, the ALCAM-binding moiety comprises at least one SRCR domain from CD6 and a stalk, such as from CD6, of the secretable or molecular form thereof.

Abstract: Methods and devices are provided for analyzing acetone in breath. One such method comprises disposing a reactant in a reaction zone within the breath analysis device, wherein the reactant comprises a primary amine disposed on a surface, and wherein the reaction zone has an optical characteristic that is at a reference level. It also comprises pre-storing a liquid nitroprusside solution within the breath analysis device separately from the reactant. The method further comprises using the breath analysis device to cause the breath to contact the reactant in the reaction zone so that the acetone in the breath reacts with the reactant to form a reaction product and, after the reaction product has been formed, using the breath analysis device to cause the nitroprusside solution to contact and react with the reaction product and to facilitate a change in the optical characteristic of the reaction zone relative to the reference level.

Abstract: Embodiments of the disclosure encompass adoptive immunotherapy related to cells expressing multiple chimeric antigen receptors (CARs). In specific embodiments, T cells express a HER2-specific CAR, an IL13R?2-specific CAR, and an EphA2-specific CAR. In particular embodiments, the cells are utilized for cancer treatment, including for glioblastoma.

Abstract: Pen-type hazardous material applicators are provided useful in applying metal pretreatment material to intricate geometries, such as blind holes, through holes, rivets, crevices, chamfers, counterbores, countersinks and other difficult to access surfaces are provided.